Novartis (NVS) receives approval in Australia for its Bexsero vaccine for protecting infants against MenB, a major cause of meningitis, adding to authorization in Europe. The drug is now licensed in over 30 countries.
In Australia, Bexsero is approved for children aged two months and older. (PR)
Meanwhile, Novartis has opened an internal probe into accusations by a former employee in China that she was instructed to bribe doctors by her manager in order to meet sales targets.